1
|
Hashemipour S, Ghobadi A, Khairkhahan SMRH, Ranjbaran M, Badri M, Ghafelehbashi SH, Gheraati M. Association of weekly or biweekly use of 50.000 IU vitamin D3 with hypervitaminosis D. Br J Clin Pharmacol 2021; 88:3506-3509. [PMID: 34927314 DOI: 10.1111/bcp.15186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 11/13/2021] [Accepted: 11/29/2021] [Indexed: 11/29/2022] Open
Abstract
Since the beginning of COVID-19 pandemic, many Iranian people are taking 50.000 IU of vitamin D3 on the weekly or biweekly bases in order to enhance their immune system function. This cross-sectional study was conducted on the patients of endocrinology clinic to compare 25(OH)D levels of weekly or biweekly consumption with the monthly users of vitamin D3 50,000 IU. The level above 100ng/ml of 25(OH)D was defined as hypervitaminosis D. Totally, 211 patients (108 and 103 patients in monthly and weekly/biweekly groups, respectively) were studied. In the subgroups of weekly and biweekly users, the rates of hypervitaminosis were 18.9% and 4.5%, respectively. In contrast, only 0.9% of monthly users had hypervitaminosis D. The highest vitamin D value of 185 ng/ml was detected in a patient who consumed 50,000 IU vitamin D3 weekly for 6 years. No hypercalcemia was detected in the patients with hypervitaminosis D.
Collapse
Affiliation(s)
- Sima Hashemipour
- Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
| | - Arefeh Ghobadi
- Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
| | | | - Mehdi Ranjbaran
- Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
| | - Milad Badri
- Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran
| | - Seyyed Hamidreza Ghafelehbashi
- Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
| | - Maryam Gheraati
- Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
| |
Collapse
|
2
|
Lakkireddy M, Gadiga SG, Malathi RD, Karra ML, Raju ISSVPM, Ragini, Chinapaka S, Baba KSSS, Kandakatla M. Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease. Sci Rep 2021; 11:10641. [PMID: 34017029 PMCID: PMC8138022 DOI: 10.1038/s41598-021-90189-4] [Citation(s) in RCA: 55] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Accepted: 05/07/2021] [Indexed: 12/13/2022] Open
Abstract
COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the impact of Pulse D therapy in reducing the inflammatory markers of COVID-19. Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0th day and 9th/11th day as per their respective BMI category. Subjects were randomised into VD and NVD groups. VD group received Pulse D therapy (targeted daily supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from 16 ± 6 ng/ml to 89 ± 32 ng/ml after Pulse D therapy in VD group and highly significant (p < 0.01) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant (p > 0.05). The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p < 0.01). Therapeutic improvement in vitamin D to 80–100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. Hence, adjunctive Pulse D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.
Collapse
Affiliation(s)
- Maheshwar Lakkireddy
- Department of Orthopaedics/ Biochemistry/ Internal Medicine , Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
| | - Srikanth Goud Gadiga
- Department of General Medicine/ Biochemistry , Gandhi Medical College, Secunderabad, Telangana, India
| | - R D Malathi
- Department of General Medicine/ Biochemistry , Gandhi Medical College, Secunderabad, Telangana, India
| | - Madhu Latha Karra
- Department of Orthopaedics/ Biochemistry/ Internal Medicine , Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India.
| | | | - Ragini
- Department of General Medicine/ Biochemistry , Gandhi Medical College, Secunderabad, Telangana, India
| | - Sangeetha Chinapaka
- Department of General Medicine/ Biochemistry , Gandhi Medical College, Secunderabad, Telangana, India
| | - K S S Sai Baba
- Department of Orthopaedics/ Biochemistry/ Internal Medicine , Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
| | - Manohar Kandakatla
- Department of Orthopaedics/ Biochemistry/ Internal Medicine , Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana, India
| |
Collapse
|